BOARD OF DIRECTORS

DR. AJAY KUMAR TYAGI

CHAIRMAN

Ajay Kumar Tyagi is the Chairman and Whole-time Director of our Company. He has been a Director of our Company since its incorporation. He holds a degree of bachelor of medicine and bachelor of surgery from LLRM Medical College, Meerut University. He also holds diploma in orthopaedics from King George Medical College, Lucknow. He has extensive experience in the field of medical care and hospital management. He is responsible for strategic investment and overall guidance for the business of our Company. He was previously associated with Medical Health Family Welfare U.P. L.K.O.

DR. KAPIL KUMAR

MANAGING DIRECTOR

Kapil Kumar is the Managing Director of our Company. He has been a Director of our Company since its incorporation. He holds a degree of bachelor of medicine and bachelor of surgery from SN Medical College, Agra University. Further, he holds a degree of master of surgery in orthopaedic surgery from Lucknow University. He has also completed magister chirurgie in orthopaedics from University of Seychelles, American Institute of Medicine. He is an orthopaedic surgeon with a vast experience in field of medicine and health care. Further, he is responsible for clinical management of our Company. He was previously associated with Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital and Noida Orthopaedic Hospital as a consultant.

MR. YATHARTH TYAGI

DIRECTOR

Mr. Yatharth Tyagi is Whole-time Director of our Company. He is responsible for overall operations and business development. He holds a bachelor’s degree in business and management from Leeds Beckett University. He also holds a master of science degree in International Health Management from Imperial College London.

Mr. Yatharth has been instrumental in bolstering performance across markets ever since joining the company. He holds the vision to bring about advancements in the field of healthcare and create institutions where patient care is delivered through innovative solutions. His leadership and unconventional strategies not only augmented healthcare capacity but have also fostered an environment of comfort and gratitude within the healthcare setting. He is ensuring the Indian healthcare system becomes robust to cater to the changing landscape of domestic and international health concerns.

INDEPENDENT DIRECTORS

MR. RAMESH KRISHNAN

INDEPENDENT DIRECTOR

Mr. Ramesh Krishnan is a seasoned healthcare leader with over 30 years of experience spanning hospital management, private equity, and strategic consulting.

Executive Director, Rela Institute and Medical Centre - September 2018 till date
Incharge of strategic planning and execution of India’s largest liver transplant centre

Operating Partner, Everstone Capital September 2018 to June 2023
Led the acquisition of the Sahyadri Hospitals network to Everstone Capital

CEO - South Asia, Parkway Pantai (IHH Healthcare) - October 2013 to August 2018
Overseeing multiple hospital acquisitions and integrations

Vice President, Fortis Healthcare, Singapore - November 2010 to October 2013
Led post-merger integrations and bolt-on acquisitions across multiple geographies

MS. PROMILA BHARDWAJ

INDEPENDENT DIRECTOR

Ms. Promila Bhardwaj is an Independent Director of our Company. She has been a Director of our Company since October 22, 2022. She holds a degree in Bachelor’s of Arts, Master’s of Arts in English and Master’s of Philosophy from Punjab University. She also holds a Master’s Diploma in Public Administration from Indian Institute of Public Administration. She Joined Indian Revenue Services (“IRS”) in 1979 and served various positions like Deputy Secretary under Ministry of Water Resources, Director of Industrial Policy and Promotion, Personal Secretary to Minister of State for Women and Child Development, Director General (HRD) (International Taxation & Transfer Pricing) & (Systems) and Chief Commissioner of Income Tax. Currently she is Independent Director in two listed companies and other public companies. She is also being member of various committees like Audit Committee, Nomination and Remuneration Committee, CSR Committee etc.

MR. MUKESH SHARMA

INDEPENDENT DIRECTOR

Mukesh Sharma is an Independent Director of our Company. He has been a Director of our Company since February 21, 2022. He holds a bachelor’s degree in science agriculture and animal husbandry from Govind Ballabh Pant University of Agriculture and Technology. He also holds a master’s degree in business administration and has completed post graduate diploma in labour law, labour welfare and personnel management from Maharshi Dayanand Saraswati University, Ajmer. Further, he holds a degree of bachelor’s of law from Chaudhary Charan Singh University, Meerut. He has over 35 years of experience in banking and was previously associated with Bank of Baroda. Currently, he is a SARFAESI Internal Ombudsman at Bank of Baroda.

DR. SANJEEV UPADHYAYA

INDEPENDENT DIRECTOR

Dr Sanjeev Upadhyaya has served as an Independent Director of the Company since February 21, 2022. He is a public health and development professional with nearly three decades of experience strengthening health systems across India and Africa.

A medical doctor by training, Dr. Upadhyaya earned his MBBS from LLRM Medical College, Meerut, and specialized in Community Medicine at the Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram. He also holds advanced credentials in Health Systems Strengthening from the Nossal Institute for Global Health, University of Melbourne, Australia.

With core expertise in maternal, newborn, and child health as well as infectious diseases, Dr. Upadhyaya spent over a decade as a Health Specialist with UNICEF across India and Africa. He has served as a Senior Advisor with USAID in New Delhi and held executive leadership as Executive Director of the State Health Systems Resource Centre (SHSRC) for the Government of Chhattisgarh. Additionally, he has consulted for leading national and international organizations, including WHO, CARE, IntraHealth  International, Handicap International, Futures Group International, and the Ministry of Health & Family Welfare, Government of India.

COMPOSITION OF COMMITTEE

Sr. No. Committee Name of Director Role in Committee Category of Director
1 Audit Committee Mr.Mukesh Sharma Member & Chairman Independent Director
Ms. Promila Bhardwaj Member Independent Director
Dr. Ajay Kumar Tyagi Member Chairman
2 Nomination and Remuneration Committee Dr. Sanjeev Upadhyaya Member & Chairman Independent Director
Mr.Mukesh Sharma Member Independent Director
Ms. Promila Bhardwaj Member Independent Director
3 Stakeholders Relationship Committee Ms. Promila Bhardwaj Member & Chairman Independent Director
Dr. Ajay Kumar Tyagi Member Chairman
Dr. Kapil Kumar Member Managing Director
4 CSR Committee Dr. Ajay Kumar Tyagi Member & Chairman Chairman
Dr. Kapil Kumar Member Managing Director
Dr. Sanjeev Upadhyaya Member Independent Director
5 Risk Management Committee Dr. Ajay Kumar Tyagi Member & Chairman Chairman
Mr. Mukesh Sharma Member Independent Director
Dr. Kapil Kumar Member Managing Director
6 Banking and Finance Committee Dr. Ajay Kumar Tyagi Member & Chairman Chairman
Dr. Kapil Kumar Member Managing Director
Mr. Yatharth Tyagi Member Whole-Time Director

KEY MANAGEMENT PERSONNEL

MR. AMIT SINGH

GROUP CHIEF EXECUTIVE OFFICER

Mr Amit Singh is a healthcare management professional with 21 years of experience in providing operations leadership, strategic planning, quality & business development with various healthcare organizations. He has been a part of the management of various premiere healthcare institutions. Prior to joining Yatharth group he has served as vice president at BLK Hospital, Delhi, group vice president at Centre for Sight group, chief operating officer at Point Hospitals and business head at Raksha Medicare. He has extensive experience of setting up a chain of hospitals. He has proven experience in field of strategic planning & policy development, business operations, administrations, sales & marketing leadership, budgeting & cost management.

MR. NITIN GUPTA

PRESIDENT - FINANCE AND GROUP CHIEF OPERATING OFFICER

Mr. Nitin Gupta is a highly accomplished finance executive with over 23 years of professional experience, including more than 19 years in the healthcare industry. A Chartered Accountant, APM alumnus of IIM Lucknow, and a graduate in Law (LLB) and B.Com. (Hons).

Throughout his career, he has played a pivotal role in strengthening financial structures and reporting systems, driving process improvements, and leading business transformation initiatives. His expertise spans Mergers & Acquisitions (M&A), Fund raising, strategic planning and execution, operational capability development, and unlocking business synergies with governance enhancement for large corporate groups.

He has served as Group CFO at Asian Hospitals, backed by leading private equity investors, and as Group Finance Controller at agilus diagnostics, a group company of Fortis Hospitals. His experience also includes leadership roles across prominent business conglomerates, where he contributed to strategic financial management, governance enhancement, and sustainable organizational growth.

MR. PANKAJ PRABHAKAR

GROUP CHIEF FINANCIAL OFFICER

Mr. Pankaj Prabhakar is a Chartered Accountant, having business experience of 23 years in accounting, cost analysis, budgeting, preparation of financial statements, internal controls, information security risk analysis. He is proficient in running successful process operations & experience of developing procedures, service standards for business of par excellence, M&A and business transformation. He has been extensively engaged in the IPO process and previously been associated with Asian Institute of Medical Sciences, Faridabad as CFO, business Analyst and Finance Head in Max Healthcare, Finance Controller in Artemis Healthcare and other leading healthcare service provider.

MR. ASHUTOSH KUMAR JHA

GROUP CHIEF – STRATEGY, M&A AND INVESTOR RELATIONS

Mr. Ashutosh Kumar Jha is an IIM and IIT alumnus with expertise in Corporate Strategy, Mergers and Acquisitions, Fund Raising and Investments. He has more than 18 years of diversified experience across healthcare and multiple other industries. He was previously associated with Artemis Hospital as Chief – Strategy, M&A, Investor Relations and Organization Growth for approx. 3 years and Max Healthcare as Director and Head - Growth and M&A for more than a year. Earlier he was associated with Private Equity and MNC firms such as Bosch Group and Maruti Suzuki in India and abroad.

MR. SONU GOYAL

GROUP CHIEF FINANCIAL CONTROLLER

Mr. Sonu Goyal is a qualified Chartered Accountant and Company Secretary. He has over 16 years of work experience, out of which more than 10 years of experience is in Hospitals. He has worked as chief finance controller in Private Equity backed healthcare firm Art Fertility clinics, as regional finance controller at Fortis Hospitals, and as finance controller at Max Hospitals.

MR. RITESH MISHRA

GROUP COMPANY SECRETARY AND COMPLIANCE OFFICER

Mr. Ritesh Mishra holds a bachelor’s degree in commerce from Awadh University, Faizabad and MBA from Sikkim Manipal University. He is an associate member of the Institute of Company Secretaries of India. He is a keen learner and adept in grasping changes in economy and its impact on health care business and stakeholders. He has rich experience the field of corporate law compliances. He extensively works with the board of the Company and instrumental in maintaining overall corporate governance at Yatharth Group of Hospitals.

CORPORATE POLICIES

Sr. No. Name of Policies Download
1 Policy on Sexual Harassment of Women at Workplace
2 Nomination & Remuneration Policy
3 Composition of Committees of Board of Directors
4 Terms and Conditions of Appointment of Independent Directors
5 Code for Independent Directors
6 Familiarization Programme for Independent Directors
7 Code of Conduct for Directors and Senior Management
8 Vigil Mechanism/ Whistle Blower Policy
9 Policy on Materiality of Related Party Transactions and on Dealing with Related Party Transactions
10 Risk Management Policy
11 Policy for Determination and Disclosure of Materiality of Events and Information
12 Criteria of making Payment to Non-Executive Directors
13 Policy on Preservation of Documents
14 Contact details of Key Managerial Personnel
15 Code of Conduct for Prevention of Insider Trading for ‘designated employees
16 Code of Practices and Procedure for Fair Disclosure of Unpublished Price
17 Policy for determining ‘material’ subsidiaries
18 Dividend Distribution Policy
19 Corporate Social Responsibility Policy
20 Policy on diversity of board of directors
21 Archival Policy
22 Materiality Policy
23 Policy on Data Privacy and Security
24 Yatharth Hospital & Trauma Care Services Employee Stock Option Scheme - 2024

CORPORATE ANNOUNCEMENTS

Sr. No. Announcements Download
1 Announcement under Reg. 30 (LODR)-Amendments to Memorandum & Articles of Association 17.09.2026
2 Announcement under Reg. 30 (LODR)-Issue of Securities 17.09.2026
3 Announcement under Reg. 30 (LODR)-Press Release 17.09.2026
4 Board Meeting Outcome -17.09.2026
5 Board Meeting Intimation 14.09.2026
6 Announcement Under Reg. 30(LODR)- Favourable Developments In Income Tax Proceedings 14.09.2026
7 Business Responsibility and Sustainability Reporting (BRSR) 03.09.2026
8 Reg. 34 (1) Annual Report FY2025-26 03.09.2026
9 Notice of 19th Annual General Meeting of the Company 03.09.2026
10 Announcement under Reg. 30 (LODR)-Newspaper Publication-22.08.2026
11 Announcement under Reg. 30 (LODR)-Intimation of Date of AGM 21.08.2026
12 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 18.08.2026
13 Announcement under Reg. 30 (LODR) - Earnings Call Recording-11.08.2026
14 Announcement under Reg. 30 (LODR)-Newspaper Publication-11.08.2026
15 Announcement under Reg. 30 (LODR)-Investor Presentation 11.08.2026
16 Announcement under Reg. 30 (LODR)- Investor Meet - Intimation 10.08.2026
17 Announcement Under Reg. 30(LODR)- ESOP Scheme 2026-10.08.2026
18 Record Date for Interim Dividend- 10.08.2026
19 Announcement under Reg. 30 (LODR)-Dividend 10.08.2026
20 Announcement under Reg. 30 (LODR)-Investor Presentation Q1FY27-10.08.2026
21 Announcement under Reg. 30 (LODR) - Press Release Q1FY27 - 10.08.2026.
22 Board Meeting Outcome For Unaudited Financial Results for Q1FY27-10.08.2026
23 Announcement Under Reg. 30 (LODR)-Grant of ESOP 10.08.2026
24 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 08.08.2026
25 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 06.08.2026
26 Board Meeting Intimation for the First Quarter FY27 04.08.2026
27 Reconciliation of Share Capital Audit Report 16.07.2026
28 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Reg. 2018 - 08.07.2026
29 Announcement under Reg. 30 (LODR)- Investor Meet - Intimation 07.07.2026
30 Intimation of the Closure of Trading Window 26.06.2026
31 Announcement under Reg. 30 (LODR) - Updates on Acquisition 12.06.2026
32 Announcement under Reg. 30 (LODR) - Investor Meet - Intimation 10.06.2026
33 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 06.06.2026
34 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 03.06.2026
35 Announcement under Reg. 30 (LODR) - Earnings Call Recording 26.05.2026
36 Announcement under Reg. 30 (LODR)- Newspaper Publication 26.05.2026
37 Announcement under Reg. 30 (LODR)- Investor Meet - Intimation 26.05.2026
38 Announcement under Reg. 30 (LODR)- Investor Presentation Q4 FY26 - 25.05.2026
39 Announcement under Reg. 30 (LODR) – Press Release Q4 FY26 – 25.05.2026.
40 Board Meeting Outcome For Audited Financial Result For Q4 & FY2026 - 25.05.2026
41 Announcement under Reg. 30 (LODR) - Earnings Conference Call Intimation (21.05.2026)
42 Board Meeting Intimation for the Fourth Quarter FY26 18.05.2026
43 Scrutinizer's Report of the Postal Ballot - 14.05.2026
44 Voting Results of the Postal Ballot - 14.05.2026
45 Outcome of the Postal Ballot - 14.05.2026
46 Announcement under Regulation 30 (LODR)-Press Release 13.05.2026
47 Announcement under Regulation 30 (LODR)-Acquisition 13.05.2026
48 Reconciliation of Share Capital Audit Report 16.04.2026
49 Announcement under Reg. 30 (LODR)-Newspaper Publication 10.04.2026
50 Initial Disclosure for Non-identification as Large Corporate 10.04.2026
51 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Reg. 2018, 10.04.2026
52 Announcement under Reg. 30 (LODR)- Notice of Postal Ballot 09.04.2026
53 Intimation of the Closure of Trading Window 27.03.2026
54 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 18.03.2026
55 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 16.03.2026
56 Personnel's authorized for determining Materiality of Events Information 25.02.2026
57 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 13.02.2026
58 Announcement under Reg. 30 (LODR)-Monitoring Agency Report- IPO 12.02.2026
59 Announcement under Reg. 30 (LODR)-Monitoring Agency Report- QIP 12.02.2026
60 Announcement under Reg. 30 (LODR)- Earnings Call Recording 06.02.2026
61 Announcement under Reg 30 (LODR)-Newspaper Publication 06.02.2026
62 Announcement under Reg 30 (LODR)-Investor Presentation- Q3 FY26 05.02.2026
63 Announcement under Reg 30 (LODR)-Press Release Q3 FY26 05.02.2026
64 Board Meeting Outcome for Unaudited Quarterly Results Q3 FY26 05.02.2026
65 Announcement under Reg. 30 (LODR)-Earnings Conference Call - Intimation 02.02.2026
66 Board Meeting Intimation for the third Quarter FY26 30.01.2026
67 Announcement under Reg. 30 (LODR)-Updates on Acquisition 29.01.2026
68 Announcement Under Reg. 30- Change of Name of Statutory Auditor 20.01.2026
69 PostalBallot_Voting Results & Scrutinizer Report
70 Reconciliation of Share Capital Audit Report 12.01.2026
71 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Reg. 2018, 06.01.2026
72 Intimation for the Closure of Trading Window 27.12.2025
73 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Reg. 2011- 17.12.2025
74 Announcement under Reg. 30 (LODR)-Newspaper Publication 17.12.2025
75 Announcement under Reg. 30 (LODR) Notice of Postal Ballot 16.12.2025
76 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 20.11.2025
77 Announcement under Reg. 30 (LODR)- Investor Meet - Intimation 18.11.2025
78 Announcement under Reg. 30 (LODR)-Newspaper Publication 14.11.2025
79 Announcement under Reg. 30 (LODR)- Earnings Call Recording 14.11.2025
80 Announcement under Reg. 30 (LODR)-Monitoring Agency Report-IPO 14.11.2025
81 Announcement under Reg. 30 (LODR)-Monitoring Agency Report-QIP 14.11.2025
82 Conference call Audio Recording
83 Announcement under Reg. 30 (LODR)-Investor Presentation 13.11.2025
84 Announcement under Reg. 30 (LODR)-Press Release 13.11.2025
85 Outcome of the Board Meeting 13.11.2025
86 Announcement Under Reg. 30 (LODR)- Update on Income Tax Matter 13.11.2025
87 Announcement under Reg. 30 (LODR)-Investor Meet_Earning Call - Intimation 11.11.2025
88 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 11.11.2025
89 Intimation of Board Meeting to be held on 13.11.2025
90 Announcement under Reg. 30 (LODR)-Credit Rating 06.11.2025
91 Intimation for Appointment of Mr. Ramesh Krishnan (Independent Director) 05.11.2025
92 Intimation Of Commencement Of Operations Of Subsidiary Company 01.11.2025
93 Reconciliation of Share Capital Audit Report 14.10.2025
94 Certificate under Reg. 74 (5) of SEBI (DP) Reg 2018 09.10.2025
95 Intimation regarding appointment of Statutory Auditor & Secretarial Auditor 30.09.2025
96 Scrutinizer Report of 18th Annual General Meeting 30.09.2025
97 Voting Results of 18th Annual General Meeting 30.09.2025
98 Proceedings of the 18th AGM of the Company 30.09.2025
99 Intimation of the Closure of Trading Window 27.09.2025
100 Announcement under Reg. 30 (LODR)-Press Release 13.09.2025
101 Announcement under Reg. 30- Acquisition of 100% interest in Shantived Institute of Medical Sciences 13.09.2025
102 Announcement under Reg. 30 (LODR)-Newspaper Publication 09.08.2025
103 Business Responsibility and Sustainability Reporting (BRSR) 08.09.2025
104 Reg. 34 (1) Annual Report 08.09.2025
105 Notice of 18th Annual General Meeting of the Company 08.09.2025
106 Announcement under Reg. 30 (LODR)-Newspaper Publication 04.09.2025
107 Announcement under Reg. 30 (LODR)-Intimation of the Date of AGM 03.09.2025
108 Announcement under Reg. 30 (LODR)-Investor Meet - Intimation 01.09.2025
109 Announcement under Reg. 30 -Analyst Investor Meet - Intimation 19.08.2025
110 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 12.08.2025
111 Monitoring Agency Report for the quarter ended June 30, 2025 - IPO 12.08.2025
112 Monitoring Agency Report for the quarter ended June 30, 2025 - QIP 12.08.2025
113 Announcement under Reg. 30 (LODR)-Press Release 11.08.2025
114 Earning Call Recording Q1 FY26 06.08.2025
115 Announcement under Regulation 30 (LODR)-Newspaper Publication 06.08.2025
116 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditors 05.08.2025
117 Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 05.08.2025
118 Investor Presentation Q1FY26 05.08.2025
119 Press Release Q1FY26 05.08.2025
120 Outcome of Board Meeting 05.08.2025
121 Announcement under Reg. 30 (LODR)- Investor Meet- Intimation 02.08.2025
122 Announcement under Reg. 30 (LODR)- Investor Meet- Intimation 01.08.2025
123 Intimation of Board Meeting to be held on 05.08.2025
124 Certificate under Regulation 74(5) 15.07.2025
125 Disclosure under Regulation 30- New Unit 14.07.2025
126 Press Release 14.07.2025
127 Press Release 03.07.2025
128 Change in Management 03.07.2025
129 Ramraja Hospital Land Dispute Award 30.06.2025
130 Closure of Trading Window 28.06.25
131 Earnings Call Transcript 04.06.2025
132 Resignation Of Mr. Neeraj Vinayak 27.05.2025
133 Earning Call Recording for Q4&FY25
134 Newspaper Publication Q 4 & FY 25_27.05.25
135 Internal Auditor Reappointment_ 27.05.2025
136 Announcement under Reg 30 (LODR)-Press Release 26.05.2025
137 Board Meeting Outcome for Audited Financial Result For Q4 & FY25 26.05.2025
138 Investor Presentation for Q4 & FY 25 26.05.2025
139 Announcement under Reg. 30 (LODR)- Investor Meet- Intimation 21.05.2025
140 Intimation of Board Meeting to be held on 26.05.2025
141 Initial Disclosure -Entity identified as a Large Corporate 17.04.2025
142 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Reg., 2018 11.04.2025
143 Resignation of Mr. Deepak Kumar Tyagi 31.03.2025
144 Intimation of Closure of Trading Window 29.03.2025
145 Announcement under Reg. 30 (LODR)-Updates on Acquisition 29.03.2025
146 Integrated Filing (Financial) 05.03.2025
147 Announcement under Reg. 30 (LODR)-Updates on Acquisition-2 29.03.2025
148 Announcement under Reg. 30 (LODR)-Earnings Call Transcript 03.02.2025
149 Announcement under Reg. 30 (LODR)-Press Release 10.02.2025
150 Information under Regulation 29(2) 10.02.2025
151 Monitoring Agency Report For Q3FY25 - IPO 06.02.2025
152 Monitoring Agency Report For Q3FY25 - QIP 06.02.2025
153 Announcement under Reg. 30 (LODR)-Investor Meet - Outcome 28.01.2025
154 Newspaper Publicaiton_Q3FY25
155 Earnings Call Recording_Q3FY25
156 Investor Presentation - Q3FY25
157 Press Release_Q3_FY25
158 Financial Results_Q3FY25
159 Investor_Meet_291124
160 Investor_Meet_271124
161 Investor_Meet_261124
162 Investor Meet 251124
163 Earning_Call_Recording_Q2FY25
164 Newspaper_Ad_Q2FY25
165 Investors_Presentation_Q2FY25
166 Press_Release_Q2FY25
167 Financial Results_Q2FY25
168 Exchange release Newspaper 21.08.24
169 Earning Call Transcript Q1FY25
170 Newspaper Publication Q1FY25
171 Monitoring Agency Report Q1FY25
172 Earning_Call_Recording_Q1FY25
173 Yatharth Hospital Press Release Q1FY25
174 Yatharth ESOP Scheme Approval
175 Yatharth Investor Presentation Q1FY25
176 Financial Results Q1FY25
177 Newspaper Financial Result
178 Q4FY24 Earning Call Recording
179 Financial Results Yatharth Q4 FY24
180 YATHARTH 10052024204254 Exchange Announcement Pristine
181 Monitoring Agency Report
182 Investor Presentation
183 Investor Meet
184 Final Report-Q3FY24-Yatharth Hospital And Trauma Care Services Limited
185 Audio link for Yatharth Hospitals Earnings Conference Q3
186 Yatharth Hospital_Q3FY24_Press release
187 Yatharth Hospital_Q3FY24_Earnings Presentation
188 Financial Result Q3 2023-24 YHTCSL
189 Acquisition Prestine Infracon
190 Investor Conference IIFL
191 Earning Conference Call Q3FY24
192 Certificate under Regulation 74(5) of the SEBI (DP) Reg, 2018.
193 Intimation of Closure of Trading Window
194 Investor Meet - 21 Dec 2023
195 Investor Meet - 20, 21 Dec 2023
196 Investor Meet - 13 Dec 2023
197 Investor Meet - 28, 30 Nov 2023
198 Transcript Yatharth Conference Call
199 Monitoring Agency Report
200 Newspaper Publications
201 Audio link for Yatharth Hospitals Earnings Conference
202 Yatharth Q2FY24 Earnings Presentation
203 Press Release Q2FY24
204 Outcome of Board Meeting
205 Yatharth Earning Conference Call Q2 FY24
206 Intimation Board Meeting
207 Intimation of Investor Meet -2
208 Intimation of Investor Meet -1
209 Intimation of Investor Meet 12.09.2023
210 Earnings ConCall Transcript Q1 FY24
211 Investor Call Recording
212 Intimation Press Release
213 Outcome of the Board Meeting
214 Analyst Investor Meet Intimation
215 Intimation of Board Meeting to be held on 17 August,2023
216 Board meeting intimation

FINANCIAL STATEMENTS

Ramraja Multispecialty Hospital & Trauma Centre Pvt. Ltd

MATERIAL CREDITORS

CORPORATE GOVERNANCE

SHAREHOLDERS INFORMATION

Notice of 19th AGM
Postal Ballot Notice 09.04.2026
Video recording of 18th AGM
Postal Ballot Notice 16.12.2025
Notice of 18th AGM
Video recording of EGM
Notice of EGM
Regulation 44 and Scrutinizers Report
Notice of 17th AGM
Newspaper Publication for 17th AGM
Video recording of 17th AGM
Disclosure Reg 30 AGM
Voting Result 17th AGM
Notice of 16th AGM
PROSPECTUS

SHAREHOLDERS INFORMATION

  • Notice of 19th AGM
  • Postal Ballot Notice 09.04.2026
  • Video recording of 18th AGM
  • Postal Ballot Notice 16.12.2025
  • Notice of 18th AGM
  • Video recording of EGM
  • Notice of EGM
  • Regulation 44 and Scrutinizers Report
  • Notice of 17th AGM
  • Newspaper Publication for 17th AGM
  • Video recording of 17th AGM
  • Disclosure Reg 30 AGM
  • Voting Result 17th AGM
  • Notice of 16th AGM
  • PROSPECTUS
  • SHAREHOLDING PATTERN

    QIP

    DISCLAIMER

    Important: You must read the following disclaimer before continuing.

    Please read this notice carefully. It applies to all persons who view this website. Viewing this information may not be lawful in certain jurisdictions. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the website. By accessing this information on this website, you agree to the terms and conditions below, including any modifications that may be made to them from time to time.

    These materials are not directed at or intended to be accessed by persons located in the United States or other jurisdictions outside India and are intended for distribution to, and use by, residents of India only.

    These materials are being made available on this website by Yatharth Hospital & Trauma Care Services Limited ("Company") solely to comply with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and the Companies Act, 2013 and the rules made thereunder, each as amended ("Companies Act"). Making the preliminary placement document dated December 18, 2024 available in electronic format on this website does not constitute an offer to sell or the solicitation of an offer to buy equity shares in the proposed qualified institutions placement ("Issue") in any jurisdiction.

    Nothing herein constitutes an offer of securities for sale in any jurisdiction where it is unlawful to do so. You are reminded that you have accessed the preliminary placement document on the basis that you are a person into whose possession the documents may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located.

    This disclaimer applies to all persons who view this website. The following disclaimer applies to the preliminary placement document in relation to the proposed qualified institutions placement of equity shares ("Equity Shares") of the company filed with BSE Limited and the National Stock Exchange of India Limited ("Stock Exchanges") ("Preliminary Placement Document"). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the preliminary placement document.

    The equity shares offered in the issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state securities laws in the United States, and unless so registered, and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any applicable U.S. state securities laws. You understand that the equity shares offered in the issue are being offered and sold only outside the United States in "offshore transactions", as defined in and in reliance on Regulation S under the U.S. Securities Act ("Regulation S") and you represent that you were outside the United States when the offer to purchase the equity shares was made to you and you are currently outside the United States and that you are not acquiring or subscribing for the equity shares as a result of any "directed selling efforts" (as defined in Regulation S).

    The preliminary placement document presented herein is placed solely to comply with the provisions of Chapter VI of the SEBI ICDR Regulations and Sections 42 and 62 of the Companies Act. Access to this website shall not form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. We are not soliciting any action or decision based on the information on this website.

    The preliminary placement document has not been and will not be filed as a prospectus or a statement in lieu of prospectus with any registrar of companies in India under the Companies Act. The preliminary placement document shall be filed as a private placement offer letter with the stock exchanges. The preliminary placement document is exclusive to the recipient and is not intended and does not constitute an offer or a solicitation or invitation of an offer to subscribe to the securities described in the preliminary placement document to the general public or any person or class of investors other than eligible qualified institutional buyers, as defined in the SEBI ICDR Regulations. The preliminary placement document has not been reviewed and approved by any regulatory authority in India or abroad, including the Securities and Exchange Board of India, Reserve Bank of India, any registrar of companies in India or any stock exchange in India. The preliminary placement document is not and should not be construed as an invitation, offer or sale of any securities to the public in India.

    None of the company, the lead managers and any of their respective affiliates, accepts any liability whatsoever, direct or indirect, that may arise from the use of the information contained on this website. Access to this website or the preliminary placement document does not constitute a recommendation by the company, the lead managers, any of their respective affiliates or any other party to subscribe to or buy or sell the equity shares. Making press announcements and other documents available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy equity shares in the company. The preliminary placement document, will not be circulated or distributed to the public in India or any other jurisdiction, and will not constitute a public offer in India or any other jurisdiction.

    The information in the preliminary placement document is as of the date thereof and neither the company, its directors nor the lead managers are under any obligation to update or revise the preliminary placement document to reflect circumstances arising after the date thereof.

    The issue, and the distribution of the preliminary placement document is being made to qualified institutional buyers as defined under the SEBI ICDR Regulations ("QIBs") which are not restricted from participating in the issue under the applicable laws, including the SEBI ICDR Regulations, are eligible to invest in this issue ("Eligible QIBs") in reliance upon Chapter VI of the SEBI ICDR Regulations and Sections 42 and 62, and other applicable provisions of the Companies Act. Unless a serially numbered preliminary placement document accompanied by an application form is addressed to a specific QIB inviting such QIB to make a bid through such application form, no offer and/or invitation of offer shall be deemed to have been made. You acknowledge that access to the preliminary placement document is intended for use by you only and you agree not to forward the preliminary placement document on to any other person, in whole or in part, or otherwise provide access via e-mail or otherwise to any other person.

    You are accessing this website at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. Neither the company, the lead managers nor any of their affiliates, directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials. It is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

    The preliminary placement document may contain statements about future events and expectations that constitute forward-looking statements. There can be no assurance that the results and events contemplated by the forward-looking statements contained there will in fact occur. The company, its directors, the lead managers or any of their respective affiliates do not make any representation or warranty, express or implied, as to, and do not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinion in the preliminary placement document.

    If you access the preliminary placement document contrary to the foregoing restrictions, you will be ineligible to purchase the securities.

    Investing in the equity shares described in the preliminary placement document presented herein involves risks and you should not invest any funds in the equity shares unless you are prepared to risk losing all or part of your investment. You are advised to carefully read the risk factors and the other information contained in the preliminary placement document presented herein before making an investment decision. You are advised to consult your own advisors about the particular consequences of investing in the equity shares described in the preliminary placement document.

    The preliminary placement document may not be downloaded, delivered, forwarded or distributed, electronically or otherwise, in whole or in part, to any other person and may not be reproduced in any manner whatsoever. Any downloading, forwarding, delivery, distribution or reproduction of the preliminary placement document in whole or in part is unauthorized. Failure to comply with this disclaimer may result in a violation of the applicable laws.

    You are accessing the materials on this website on the basis that you are a person into whose possession these material may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located. If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

    I certify that I am authorized to access this site.

    Confirmation

    To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access, you:

    • Are located and resident in India
    • Are not a resident of the United States and you are not located inside the United States
    • Are eligible to invest

    Select Country

    Please indicate which country you are accessing the document from:

    SECRETARIAL COMPLIANCE REPORT

    Annual Secretarial Compliance Report 31.03.2025
    Annual Secretarial Compliance Report 31.03.2026
    Annual Secretarial Compliance Report 31.03.2024

    MEMORANDUM AND ARTICLES OF ASSOCIATION

    Memorandum and Articles of Association

    MONITORING AGENCY REPORT

    Monitoring Agency Report - IPO Q1 FY 2026-27
    Monitoring Agency Report - QIP Q4 FY 2025-26
    Monitoring Agency Report - IPO Q4 FY 2025-26
    Monitoring Agency Report- IPO Q3 FY 2025-26
    Monitoring Agency Report- QIP Q3 FY 2025-26
    Monitoring Agency Report- IPO Q2 FY 2025-26
    Monitoring Agency Report- QIP Q2 FY 2025-26
    Monitoring Agency Report- IPO Q1 FY 2025-26
    Monitoring Agency Report- QIP Q1 FY 2025-26
    Monitoring Agency Report- QIP Q4 FY 2024-25
    Monitoring Agency Report- IPO Q4 FY 2024-25
    Monitoring Agency Report Q3 FY 2024-25
    Monitoring Agency Report Q2 FY 2024-25
    Monitoring Agency Report Q1 FY 2024-25
    Monitoring Agency Report Q4 FY 2023-24
    Monitoring Agency Report Q3 FY 2023-24
    Monitoring Agency Report Q2 FY 2023-24

    GRIEVANCE & REDRESSAL

    REGISTRAR & SHARE TRANSFER AGENT

    MUFG Intime India Private Limited
    (Formerly Known as Link Intime India Pvt. Ltd.)
    C-101, 1st Floor, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
    Contact No: +91 - 8108116767
    E-mail: 1- investor.helpdesk@in.mpms.mufg.com
                 2- yatharth.ipo@linkintime.co.in
    Contact Person: Shanti Gopalkrishnan
    URL of SEBI Website: Click here
    SEBI Reg. No.: INR000004058
    CIN: U67190MH1999PTC118368


       

    Mr Ritesh Mishra

    Company Secretary & Compliance Officer
    E-mail : compliance@yatharthhospitals.com
    Tel : +911206811236
    Address : Sovereign Capital Gate, FC-12 Sector 16A, Noida – 201301

       

    Online Dispute Resolution (SMART ODR)

    Website: https://smartodr.in/login
    Email: help@smartodr.in
    Helpline No: +91 - 8105148710

       

    SEBI Complaint Redress System (SCORES)

    Website: https://scores.sebi.gov.in/
    Email: scoreshelp@sebi.gov.in
    Helpline No: 1800 266 7575 or 1800 22 7575